- Piramal | Healthcare was the first contract supplier of ADCs globally
GRANGEMOUTH, Scotland, July 26, 2013 /CNW/ - Piramal's Healthcare
vertical today announced that it is to invest USD 2.5 million at its
FDA approved Grangemouth, UK, site to upgrade one of its antibody drug
conjugate (ADC) manufacturing suites, from clinical phase to commercial
grade, in response to customer demand. The upgrade will give Piramal
two commercial grade ADC suites at the Grangemouth facility, while
retaining clinical phase manufacturing capacity in other suites on
(Logo: http://photos.prnewswire.com/prnh/20130724/629310 )
ADCs are targeted therapies designed to deliver a drug payload to cancer
cells while minimising the adverse effects on normal healthy cell and
Piramal | Healthcare was the first contract supplier of ADCs globally.
The batch size offered from the Grangemouth facility ranges from 1-1.5kg
and Piramal has capacity for further expansion on site if required. As
part of the investment, the areas supporting the manufacturing suite
will also be upgraded to provide new areas for buffer preparation,
equipment preparation and antibody freeze / thaw.
Piramal also intends to expand its "Proof of Concept" (POC) offer at
Grangemouth, for pharma companies looking to demonstrate antibody
and/or toxin suitability for use as an ADC.
"Piramal was a pioneer when it came to the commercial manufacture of
ADCs" commented Aidan Walker, President, Formulation Services. "Continued growth in the ADC market and customer demand have led to
this latest investment. As part of our POC offer we draw on our vast
experience in ADCs to supply model antibodies, the corresponding target
cell lines, and non proprietary toxins, to demonstrate suitability of
client materials for use in ADC conjugation. We have worked on over
65 ADC candidates and over 30 different ADC drug linkers to date and
also have experience with PEGylation, chelating conjugates for
radioimmunotherapy and protein toxin conjugates."
Vijay Shah, Executive Director & Chief Operating Officer of Piramal Enterprises, added, "This investment, supporting an emerging and exciting platform
in the field of oncology treatment, aligns completely with our values
as an organisation. We view ADCs as a strategic area of growth for our
Pharma Solutions Business and this investment demonstrates our
intention to support our customers with facilities and capacity that
can support them into commercial supply".
The announcement follows the news in October 2012 that Piramal had
formed an alliance with Fujifilm Diosynth Biotechnologies through which
the two companies offer seamless contract development and manufacture
About Piramal | Healthcare:
Piramal | Healthcare is a part of the Piramal Enterprises Ltd. Led by
Ajay G. Piramal, the Piramal Group is one of India's foremost business
conglomerates. Emerging from a rich textile industry lineage, the
Piramal Group has exemplified diversification by foraying into a myriad
of industries that encompass healthcare, drug discovery and research,
glass, real estate and financial services.
Piramal Enterprises, Piramal Life Sciences, Piramal Glass and Piramal
Realty are the flagship companies that operate within these sectors.
The Piramal Group truly demonstrates a global footprint with its
products and services being exported to over 100 countries, its
international income contributing to greater than 70% of the Group's
revenues and more than 15 nationalities being represented amongst its
employees. http://www.piramal.com To know more, visit http://www.piramalpharmasolutions.com/
SOURCE: Piramal Enterprises Ltd.
For further information:
For Media Queries:
Contact: +91-22-3351-4082 / 4083
PUBLIC RELATIONS CONSULTANT